Malignant melanoma requires a multidisciplinary treatment approach that incorporates surgery, radiotherapy, immunotherapy, and small molecule-targeted therapies. Treatment decisions are influenced by disease stage, resectability, and in the unresectable or metastatic setting, BRAF-mutation status. The malignant melanoma landscape has transformed since 2011: CTLA-4 inhibitors, PD-1 inhibitors, and BRAF/MEK inhibitors are now key treatment options for unresectable disease while adjuvant cytokine therapy remains the mainstay for early-stage disease. This analysis provides insight on current use of approved therapies for malignant melanoma in the EU5 and on factors driving physicians’ prescribing decisions.


Related Reports

Malignant Melanoma - Landscape & Forecast - Disease Landscape & Forecast

The introduction of immune checkpoint inhibitor therapies, Keytruda (Merck & Co.) and Opdivo ± Yervoy (Bristol-Myers Squibb), as well as

View Details

Malignant Melanoma - Current Treatment - Detailed, Expanded Analysis: Treatment Sequencing (US)

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into...

View Details

Malignant Melanoma - Current Treatment - Detailed, Expanded Analysis (US)

Stage of disease, resectability of the primary tumor, and BRAF mutation status are key parameters influencing the treatment paradigm of malignant melanoma. BRAF/MEK inhibitor combination r...

View Details

Malignant Melanoma | Disease Landscape and Forecast | G7 | 2019

Although the malignant melanoma market has become increasingly crowded, an evolving trend of combining drug classes to create novel therapies is expanding treatment options for patients. While both...

View Details